🦠 Pioneering Singapore Pilot Study Links Respiratory Bacteria to Lung Cancer Risk

In a groundbreaking development for biomedical research in Singapore, scientists from the National University of Singapore (NUS) and Duke-NUS Medical School have published the first pilot case-control study examining bacterial associations with lung cancer in Southeast Asian patients. Titled "Bacterial taxa associated with lung cancer cases in Southeast Asians," this research, appearing in Cellular Oncology on April 10, 2026, reveals distinct microbiota signatures in sputum samples from lung cancer patients compared to healthy controls. Conducted amid Singapore's multiethnic population, the study highlights how disruptions in the respiratory microbiome— the community of microorganisms in the airways—may contribute to lung carcinogenesis, the process by which normal lung cells transform into cancer cells.

Lung cancer remains the leading cause of cancer mortality in Singapore, claiming thousands of lives annually despite advances in screening and therapy. According to the Singapore Cancer Registry, from 1968 to 2021, over 53,000 cases were recorded, with 81.6% diagnosed at advanced stages III or IV, underscoring the urgent need for early detection biomarkers. This pilot study, involving 70 lung cancer patients primarily from Changi General Hospital, National Cancer Centre Singapore (NCCS), and Singapore General Hospital, alongside 47 healthy controls, provides preliminary evidence that specific bacterial genera could serve as indicators of disease risk in Southeast Asians.

The Burden of Lung Cancer in Singapore and Southeast Asia

Singapore faces a significant lung cancer challenge, with age-standardized incidence rates among the highest in Southeast Asia. In 2022, the region saw 1,146,810 new cancer cases, driven by lung cancer in men and breast cancer in women, projecting a near doubling by 2050 to 2.03 million annually. In Singapore specifically, lung cancer accounts for 13.2% of male cancer cases and remains a top killer, even as overall cancer death rates have declined 21% since 2012 due to improved treatments.

What sets Southeast Asian cases apart? High rates among never-smokers, particularly women, and adenocarcinoma subtype predominance suggest environmental and microbial factors beyond smoking. Multiethnic demographics—Chinese, Malay, Indian—add complexity, as genetic and lifestyle variations influence microbiome composition. This study addresses a critical gap, being the first region-specific probe into airway bacteria's role.

Spotlight on Singapore's Research Powerhouses: NUS, Duke-NUS, and Collaborators

Leading the effort is Yann Felix Boucher from NUS's Saw Swee Hock School of Public Health and Singapore Centre for Environmental Life Sciences Engineering (SCELSE), a hub for microbiome research. Co-authors include Darren Wan Teck Lim from Duke-NUS Medical School and NCCS, and Jonathan Wei Jie Lee from NUS Yong Loo Lin School of Medicine. Contributions from NTU's Lee Kong Chian School of Medicine (LKCMedicine) via researchers like Fransiskus X. Ivan underscore inter-university collaboration.

NUS's SCELSE pioneers environmental microbiome studies, while Duke-NUS excels in translational cancer research. NTU's recent Centre for Microbiome Medicine (launched 2022) focuses on respiratory and metabolic links. These institutions position Singapore as a global leader, attracting talent through programs like the Academic Respiratory Initiative for Pulmonary Health (TARIPH).

🔬 Unpacking the Study Methods: From Sputum to Sequencing

Sputum—mucus coughed up from the lower respiratory tract—was collected pre-treatment from patients (80.9% stage IV, mostly adenocarcinoma) and controls. DNA extraction used standardized kits, followed by 16S rRNA gene sequencing (V3-V4 region) on Illumina MiSeq, processing via QIIME 2 for denoising and rarefaction. Diversity metrics (alpha: Shannon index; beta: Aitchison distance) and differential abundance (ANCOM-BC2, adjusted for confounders like sex, age, smoking) were analyzed, with random forest modeling for classification accuracy.

This rigorous, protocol-matched approach minimized batch effects, enabling robust comparisons in a multiethnic cohort reflecting Singapore's diversity.

Key Findings: Bacterial Signatures That Stand Out

• Reduced Diversity: Lung cancer cases exhibited lower genus richness (Observed ASVs, Shannon index), indicating dysbiosis—imbalance in microbial communities.
• Enriched Taxa: Lactobacillus significantly higher in cases, especially males (q<0.001), potentially modulating tumor immunity via lactate production.
• Depleted Taxa (Protective?): [Eubacterium] nodatum group, Mogibacterium, Campylobacter consistently lower in cases, robust across tests including never-smokers.
• Classifier Performance: Random forest using top 20 genera achieved 87.5% accuracy distinguishing cases from controls.
• Sex-Specific Patterns: Male cases showed Lactobacillus enrichment; female differences subtler, like Klebsiella.

Cancer subtypes further stratified microbiota, with small-cell lung cancer differing from non-small cell.

Photo by Joshua Kettle on Unsplash

Implications for Early Detection and Personalized Medicine

These findings suggest respiratory bacteria could serve as non-invasive biomarkers for lung cancer risk stratification in Southeast Asians, where environmental exposures (pollution, diet) shape unique microbiomes. Lactobacillus's enrichment aligns with its opportunistic role in dysbiosis; depleted taxa like Mogibacterium may confer protection via anti-inflammatory effects. A full study is available here.

For Singapore, this bolsters precision oncology at NCCS and universities, potentially integrating microbiota profiling into screening for high-risk groups like never-smokers.

Singapore's Microbiome Ecosystem: Building on Strong Foundations

NUS SCELSE and NTU's Centre for Microbiome Medicine lead respiratory microbiome probes, linking bacteria to ageing and chronic diseases. Duke-NUS complements with cancer-focused translations. Recent initiatives like GLOW (gut microbiome-mental health) exemplify Singapore's holistic approach.

Funding from NRF and A*STAR fuels such work, fostering PhD/postdoc training in bioinformatics and metagenomics.

Challenges, Limitations, and the Road Ahead

As a pilot, limitations include cross-sectional design (no causality), hospital-based cases (selection bias), and control mismatch. Future longitudinal cohorts, multi-omics integration (metabolomics, host genomics), and functional assays are needed. Region-specific validation is crucial given SE Asia's diversity.

Singapore universities plan expansions via TARIPH, aiming for clinical trials on microbiota modulation (probiotics?) for prevention.

Career Opportunities in Singapore's Thriving Biomed Sector

This study exemplifies opportunities at NUS, NTU, Duke-NUS for microbiomics experts. Roles in sputum analysis, AI classifiers, and trials abound, with competitive salaries and global impact. Singapore's ecosystem supports early-career researchers via fellowships.NCCS statistics highlight ongoing needs.

Broader Impacts: From Bench to Policy in Singapore

By spotlighting microbial dysbiosis, the study informs public health—air quality, antibiotics stewardship—affecting Singapore's aging population. Universities drive policy via evidence, positioning graduates for leadership in oncology-microbiome fusion.

Stakeholders like MOH and A*STAR praise such interdisciplinary work, promising expanded grants.

Photo by Joshua Kettle on Unsplash

Expert Perspectives and Stakeholder Views

Lead author Yann Felix Boucher notes: "Distinct environmental exposures in Southeast Asia necessitate region-specific investigations." Collaborators emphasize validation: "Larger cohorts will clarify clinical utility."

Patients and oncologists welcome non-invasive tools amid rising never-smoker cases.